Table 2.
Laboratory findings of patients with COVID-19.
| All patients (n = 47) | Hospitalization days < 21 (n = 20) | Hospitalization days ≥ 21 (n = 27) | P value | |
|---|---|---|---|---|
| Laboratory findings | ||||
| Leucocytes (*10^9/L) | 5.47 (4.40–6.48) | 5.43 (4.40–6.35) | 5.75 (3.81–6.48) | 0.29 |
| < 3.5 (%) | 6 (12.77) | 0 | 6 (22.22) | 0.03 |
| Neutrophil (*10^9/L) | 3.23 (2.43–3.87) | 3.22 (2.46–3.81) | 3.41 (2.43–4.06) | 0.31 |
| Lymphocytes (*10^9/L) | 1.55 (1.10–1.94) | 1.56 (1.12–1.90) | 1.44 (1.03–1.88) | 0.57 |
| < 1.1 (%) | 12 (25.53) | 3 (15.00) | 9 (33.33) | 0.28 |
| Neutrophil-to-Lymphocyte ratio | 2.10 (1.56–2.92) | 1.83 (1.53–3.37) | 2.37 (1.63–2.83) | 0.78 |
| Monocytes (*10^9/L) | 0.48 (0.36–0.62) | 0.44 (0.34–0.54) | 0.48 (0.38–0.65) | 0.76 |
| Platelet (*10^9/L) | 228 (190–265) | 236 (203–262) | 212 (187–269) | 0.66 |
| Erythrocyte sedimentation rate (mm/h) | 17 (11–22) (n = 10) | 18 (16–19) (n = 2) | 17 (9–30) (n = 8) | > 0.99 |
| Prothrombin time (S) | 11.5 (11–11.8) (n = 43) | 11.4 (11–11.6) (n = 19) | 11.6 (11–11.8) (n = 24) | 0.71 |
| > 13 (%) | 2 (4.26) | 1 (5.00) | 1 (3.70) | > 0.99 |
| D-dimer (mg/L) | 0.32 (0.26–0.47) | 0.38 (0.28–0.52) | 0.29 (0.25–0.36) | 0.13 |
| Creatine kinase (U/L) | 69 (44–103) | 58 (42–93) | 72 (52–108) | 0.57 |
| Creatine kinase isoenzyme (U/L) | 14 (10–17) | 11 (8–15) | 15 (12–18) | 0.57 |
| Lactic dehydrogenase (U/L) | 172 (149–203) | 159 (144–188) | 176 (156–208) | 0.41 |
| Albumin (g/L) | 39.2 (36.3–42.1) | 38.1 (35.9–41.8) | 39.4 (37.1–42.5) | 0.68 |
| Albumin -to-Globulin ratio | 1.4 (1.3–1.5) | 1.3 (1.1–1.5) | 0.65 | |
| < 1.2 (%) | 12 (25.53) | 3 (15.00) | 9 (33.33) | 0.28 |
| Alanine transaminase (U/L) | 23 (14–34) | 24 (12–35) | 23 (15–28) | 0.63 |
| > 40 (%) | 8 (17.02) | 2 (10.00) | 6 (22.22) | 0.48 |
| Aspartate aminotransferase (U/L) | 24 (19–30) | 20 (16–26) | 27 (21–32) | 0.13 |
| > 35 (%) | 5 (10.64) | 1 (5.00) | 4 (14.81) | 0.55 |
| Total bilirubin (μmol/L) | 15.9 (11.3–23.9) | 17.8 (9–24.2) | 15.5 (11.7–21.0) | 0.78 |
| Blood urea nitrogen (mmol/L) | 3.56 (2.93–4.08) | 3.58 (2.88–4.04) | 3.56 (3.05–4.08) | 0.74 |
| Creatinine (μmol/L) | 64.6 (53.9–77.6) | 57 (51.1–70.9) | 68.7 (57.1–80.2) | 0.15 |
| Troponin I (ng/ml) | 0.002 (0.001–0.003) (n = 39) | 0.001 (0.001–0.003) (n = 15) | 0.003 (0.001–0.003) (n = 24) | 0.33 |
| Procalcitonin > 0.1 ng/ml (percentage, %) | 2 (4.88) (n = 41) | 2 (10.00) | 0 | 0.18 |
| C-reactive protein (mg/L) | 3.65 (0.51–14.4) | 0.52 (0.49–4.09) | 6.33 (3.42–18.9) | 0.01 |
| Complement C3 | 0.81 (0.74–0.95) (n = 45) | 0.78 (0.69–0.88) (n = 19) | 0.85 (0.75–1.08) (n = 26) | 0.04 |
| Complement C4 | 0.2 (0.15–0.3) (n = 45) | 0.18 (0.15–0.22) (n = 19) | 0.23 (0.18–0.36) (n = 26) | 0.09 |
| Negative conversion time of SARS-CoV-2 RNA after onset of symptoms | 24 (16–30) | 16 (14–21) | 30 (25–34) | < 0.001 |
| Positive for influenza A/B/RS virus IgM | 14 (29.79) | 4 (20.00) | 10 (37.04) | 0.35 |
| Imaging features | ||||
| Flaky/patchy shadows | 39 (82.98) | 14 (70.00) | 25 (92.59) | 0.10 |
| Ground glass shadow | 29 (61.70) | 13 (65.00) | 16 (59.26) | 0.69 |
| Broncho meteorology | 22 (46.81) | 4 (20.00) | 18 (66.67) | < 0.01 |
| Halo/anti-halo sign | 5 (10.64) | 1 (5.00) | 4 (14.81) | 0.55 |
| Consolidation | 12 (25.53) | 2 (10.00) | 10 (37.04) | 0.08 |
| Peripheral tape, subpleural | 30 (63.83) | 10 (50.00) | 20 (74.07) | 0.09 |